Report : Middle East & Africa Upstream Bioprocessing Market Forecast to 2030 - Regional analysis - by Product Type (Bioreactors/Fermenters, Cell Culture, Filters, Bags and Containers, and Others), Workflow (Media Preparation, Cell Culture, and Cell Separation), Usage Type (Single-use and Multi-use), and Mode (In-house and Outsourced)
At 12.6% CAGR, Middle East & Africa Upstream Bioprocessing Market is Projected to be Worth US$ 712.66 Million by 2030, says Business Market Insights.
According to Business Market Insights' research, the Middle East & Africa upstream bioprocessing market was valued at US$ 275.22 million in 2022 and is expected to reach US$ 712.66 million by 2030, registering a CAGR of 12.6% from 2022 to 2030. Commercial use of single-use bioreactors and Technological advancements are among the critical factors attributed to the Middle East & Africa upstream bioprocessing market expansion.
Various manufacturers are developing single-use bioreactors (SUBs) due to their robust build and high performance, which are necessary for the commercial manufacturing of biopharmaceuticals. The incorporation of technologies associated with biofilm formation, stirring mechanisms, bioreactor designs, and sensor systems, among others, have resulted in the increased adoption of disposable reactors at the laboratory and production scales. Single-use bioreactors are operated to manufacture next-generation cell and gene therapies, and they are suitable for continuous bioprocessing. Advancements in cell-culture processes have developed higher titers and cell densities, facilitating the adoption of SUBs. Single-use bioreactors operate with a low risk of contamination, shorter production turnaround times, and reduced validation time. In the last few years, the use of single-use bioreactors has increased in modern biopharmaceutical processes owing to their unique ability to aid enhanced flexibility, reduce investments, and limit operational costs. Also, many companies have developed single-use bioreactors for producing a wide range of therapeutics. In March 2021, Thermo Fischer Scientific launched the 3,000 L and 5,000 L HyPerforma DynaDrive single-use bioreactors. Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10-15 mL micro bioreactor scale and Biostat STR for 50-2000L. The use of single-use bioreactors is subsequently increasing in upstream bioprocessing. Thus, the increasing acceptance of single-use bioreactors for the production of therapeutics propels the upstream bioprocessing market.
On the contrary, stringent regulatory framework hampers the growth of Middle East & Africa upstream bioprocessing market.
Based on product type, the Middle East & Africa upstream bioprocessing market is segmented into bioreactors/fermenters, cell culture, filters, bags and containers, and others. The bioreactors/fermenters segment held 35.6% market share in 2022, amassing US$ 97.87 million. It is projected to garner US$ 248.67 million by 2030 to expand at 12.4% CAGR during 2022-2030.
Based on workflow, the Middle East & Africa upstream bioprocessing market is segmented into media preparation, cell culture, and cell separation. The cell separation segment held 44.4% share of Middle East & Africa upstream bioprocessing market in 2022, amassing US$ 122.16 million. It is projected to garner US$ 325.53 million by 2030 to expand at 13.0% CAGR during 2022-2030.
By usage type, the Middle East & Africa upstream bioprocessing market is bifurcated into single-use and multi-use. The single-use segment held 55.5% share of Middle East & Africa upstream bioprocessing market in 2022, amassing US$ 152.64 million. It is projected to garner US$ 402.12 million by 2030 to expand at 12.9% CAGR during 2022-2030.
In terms of mode, the Middle East & Africa upstream bioprocessing market is bifurcated into In-house and outsourced. The In-house segment held 63.9% share of Middle East & Africa upstream bioprocessing market in 2022, amassing US$ 175.84 million. It is projected to garner US$ 447.49 million by 2030 to expand at 12.4% CAGR during 2022-2030.
Based on country, the Middle East & Africa upstream bioprocessing market has been categorized into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 34.6% share of Middle East & Africa upstream bioprocessing market in 2022. It was assessed at US$ 95.12 million in 2022 and is likely to hit US$ 249.61 million by 2030, exhibiting a CAGR of 12.8% during 2022-2030.
Key players operating in the Middle East & Africa upstream bioprocessing market are Thermo Fisher Scientific Inc, Esco Micro Pte Ltd, Sartorius AG, Danaher Corp, Getinge AB, Merck KGaA, and Corning Inc, among others.
- In January 2023, Sartorius collaborated with RoosterBio Inc to address purification challenges and establish scalable downstream manufacturing processes for exosome-based therapies. Through this collaboration, Sartorius and RoosterBio will provide best-in-class solutions and expertise for a human mesenchymal stem/stromal cell (hMSC) - based exosome production platform that delivers industry-leading yield, purity, and potency.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com